Utilizing Upadacitinib for the Management of Hailey-Hailey Disease
Main Article Content
Keywords
upadacitinib, janus kinase inhibitors, hailey hailey disease
Abstract
Hailey-Hailey Disease (HHD) is a rare disease associated with mutation of the ATP2C1 gene characterized by skin blistering and erosion. Here, we report a case of a patient with HHD who significantly improved after treatment with upadacitinib. A 55-year-old male with biopsy-confirmed Hailey-Hailey disease presented with a 20-year history of ill-defined, brightly erythematous, painful patches initially on the neck and subsequently involving the penile shaft. Following treatment with 30mg of upadacitinib, the patients neck ulcers gradually re-epithelized. This case adds to the growing body of literature supporting the use of Janus kinase inhibitors as a therapeutic modality for this condition.
References
2. Ben Lagha I, Ashack K, Khachemoune A. Hailey–Hailey Disease: An Update Review with a Focus on Treatment Data. Am J Clin Dermatol. 2020;21(1):49-68. doi:10.1007/S40257-019-00477-Z/METRICS
3. Solimani F, Meier K, Ghoreschi K. Emerging Topical and Systemic JAK Inhibitors in Dermatology. Front Immunol. 2019;10:2847. doi:10.3389/FIMMU.2019.02847/FULL
4. Murphy L, Ch’en P, Song EJ. Refractory Hailey–Hailey disease cleared with upadacitinib. JAAD Case Reports. 2023;41:64-67. doi:10.1016/J.JDCR.2023.09.011
5. Zeinali R. Successful treatment of recalcitrant severe Hailey-Hailey disease with tofacitinib Case Report Journal of Clinical Images and Medical Case Reports. Open Access. 5. doi:10.52768/2766-7820/3099
6. Liu W, Xue X, Li S. Treatment of Hailey-Hailey disease with biologics and small molecule inhibitors: a 1 systematic review 2 3. doi:10.1093/ced/llae298/7726937
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.